Triple-negative breast cancer (TNBC) that do not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) represent an aggressive subgroup of breast cancer (Brewster et al., 2014) with poor prognosis and limited treatment options in the clinic (Foulkes et al., 2010). Here, ERBB2 is linked to breast carcinoma.